Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3295MR)

This product GTTS-WQ3295MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3295MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7415MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ9629MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ13706MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ5008MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ1468MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ6447MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ1900MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ15348MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TRC-105
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW